Intensity Therapeutics’ Phase 3 sarcoma study authorized to continue by DMC

Intensity Therapeutics (INTS) announced that following its most recent periodic review meeting, the Data Monitoring Committee, or DMC, overseeing the company’s ongoing Phase 3 sarcoma study of INT230-6 has agreed that the study should continue without modification. The DMC reviewed data covering the six months from July to December 2024. The INVINCIBLE-3 Study is a global open-label, randomized, controlled study designed to evaluate INT230-6 administered intratumorally by an interventional radiologist or an equivalently trained physician using image guidance compared to systemically dosed standard of care chemotherapy. The study endpoints are overall survival and safety, along with an exploratory quality of life assessment. The study is testing the efficacy and safety of INT230-6 intratumoral injection compared to any of three standard-of-care therapies.